Soaring Hepatitis C Drug Prices Make Cures Costly
The arrival of Vertex's (VRTX) Incivek in 2010 kicked off a significant jump in the costs of treating hepatitis C. Those costs are likely to surge higher once Gilead's (GILD) and Johnson & Johnson's (JNJ) new drugs launch.
Johnson & Johnson Wins Hep C Battle, but War Doesn't Look Good
Johnson & Johnson beats Gilead Sciences to deliver the first next-generation hepatitis C drug approved in the U.S., but a battle with Vertex Pharmaceuticals' and Merck's first-generation drugs will be short lived with Gilead and AbbVie developing all-oral cocktails.
Johnson & Johnson Gives Vertex Upfront Cash to Stop Paying Royalty on Hepatitis C Drug Incivo
Vertex sells royalty rights to hepatitis C drug Incivo to partner Johnson & Johnson for $152 million.